Adults with primary membranous nephropathy now have a drug approved specifically for their condition. The Food and Drug Administration listed its decision Nov. 13, and the drugmaker announced it Sunday night in the United States. The new use for Gazyva, also called obinutuzumab, is for adults at risk of worsening disease, to reduce the amount of protein leaking into their urine.

This is the first FDA approval for the condition itself. Gazyva has been available in the United States since 2013 and already had approvals for certain blood cancers and other kidney conditions. The new approval covers a different diagnosis. FDA approval notice

Who the new approval covers

Silver-stained kidney biopsy tissue affected by membranous nephropathy
A microscope photograph shows how membranous nephropathy affects the kidney’s tiny filtering structures.Nephron via Wikimedia Commons · CC BY-SA 3.0

In primary membranous nephropathy, the immune system damages the tiny filters that clean the blood in the kidneys. The injured filters let too much protein pass into the urine. Some people notice foamy urine, swelling around the ankles or eyes, or fatigue. Persistent protein loss can lead to complications and eventually kidney failure.

A kidney specialist can use urine and blood tests to measure how much protein is being lost and how well the kidneys filter the blood. A kidney biopsy can also help establish the diagnosis. The National Kidney Foundation distinguishes primary disease from secondary membranous nephropathy, which can have a separate cause such as another illness or a medication. The FDA's new indication is for primary disease in adults whose condition is at risk of progressing. Some patients with membranous nephropathy go into remission with time or receive supportive care first. National Kidney Foundation overview

What the two-year trial measured

The FDA reviewed a randomized study of 142 adults. Half were assigned to Gazyva, an intravenous infusion. The other half were assigned to tacrolimus, an oral drug sometimes used off-label for this disease. At week 104, about 36% of the people assigned to Gazyva had achieved complete remission of proteinuria, compared with about 6% on tacrolimus. Patients and investigators knew which treatment participants received. Published trial abstract

To count as complete remission, patients had to meet a urine protein-to-creatinine threshold of 0.3 grams per gram or less and have stable estimated kidney filtration at the end of two years. The trial did not count patients as having complete remission if they needed rescue treatment, experienced treatment failure or left the study early. The 36% figure describes how often adults in the trial met that definition at two years. It does not give an individual patient's chance of avoiding dialysis or show that the disease is cured. FDA review of the trial results

What treatment would involve

FDA sign in front of Building 21 in Silver Spring, Maryland
The FDA’s Center for Drug Evaluation and Research in Silver Spring, Maryland, photographed in 2010.U.S. Food and Drug Administration via Wikimedia Commons (public domain)

A healthcare professional gives Gazyva through a vein. The November prescribing information calls for four initial infusions for this use, at the first visit and at weeks two, 24 and 26. The label also describes when additional treatment may be considered. This means planning for several clinic visits over roughly six months, along with any testing the care team orders.

The drug carries a boxed warning for reactivation of hepatitis B and for progressive multifocal leukoencephalopathy, a rare, serious brain infection. The prescribing information calls for hepatitis B screening before treatment. The FDA reported that infusion reactions and upper respiratory infections were among the most common side effects in the study. The prescriber can explain how the team monitors for reactions and what a patient's infection history means for treatment.

At an appointment, patients can ask which lab results put their kidney function at risk, how the specialist would measure a response and whether an infusion center is available through their plan. The approval notice does not set a copay or require an insurer to cover a particular site of care. The plan and infusion center can confirm coverage and any separate facility charges before treatment begins.